Proposal of remission criteria for IgA nephropathy
- 608 Downloads
The remission criteria of immunoglobulin A (IgA) nephropathy have varied depending on the clinical study. Therefore, nephrologists cannot make a uniform assessment of treatment outcomes and the standardization of explanations of the condition is difficult in patients with IgA nephropathy. This study aims to propose clinical remission criteria for IgA nephropathy based on a nationwide opinion survey in Japan regarding IgA nephropathy remission/relapse.
This nationwide survey was sent to 312 teaching facilities of the Japanese Society of Nephrology by Progressive Renal Disease Research, Research on Intractable Disease, from the Ministry of Health, Labour and Welfare of Japan.
Valid answers were obtained from 193 facilities (61.9 %) (136 internal medicine facilities and 57 pediatric facilities), of which 134 (69.4 %) thought that both hematuria and proteinuria should be used in the remission standards. Approximately half of the survey respondents shared the opinion on standards of negative results for hematuria and proteinuria and the duration and frequency of these conditions.
In this paper, we propose a standardized set of criteria for defining IgA nephropathy remission: three consecutive negative results over a 6-month period in urinary occult blood tests; urinary sediment red blood cell count of <5/high-power field (hematuria remission); and urinary protein of <0.3 g/day (g/g Cr; proteinuria remission). Clinical remission is defined as cases with both hematuria and proteinuria remission. These consensus-based remission criteria should be verified in future studies. In the meantime, they may be useful in predicting therapeutic outcome in cases of IgA nephropathy.
KeywordsRemission criteria IgA nephropathy Hematuria Proteinuria
We thank the fellows of the Japanese Society of Nephrology who responded to our questionnaire. This study was supported in a part by a Grant-in Aid for Progressive Renal Diseases Research, Research on Intractable Disease, from the Ministry of Health, Labour and Welfare of Japan. The authors are grateful to F. Shimazawa and E. Katayama of Juntendo University, Faculty of Medicine for their excellent clerical assistance.
Conflict of interest
The authors have declared that no conflict of interest exists.
- 4.Matsuzaki K, Suzuki Y, Nakata J et al. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013 (epub ahead of print). http://link.springer.com/content/pdf/10.1007%2Fs10157-013-0779-7. Accessed 22 March 2013.
- 16.Scientific Committee, Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Tokyo: Tokyo Igakusya; 2009.Google Scholar
- 17.Commitee for Diagnostic Guidelines of Hematuria. Guidelines for diagnosis of hematuria. Nihon Jinzo Gakkai Shi. 2006;48(Suppl):1–34.Google Scholar
- 18.Committee of revision of clinical practice guidebook 2012 for diagnosis and treatment of CKD. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Tokyo: Tokyo Igakusha; 2012.Google Scholar
- 19.Japanese Society of Nephrology. Nephrotic syndrome diagnosis guidelines. Nihon Jinzo Gakkai Shi. 2011;53:78–122.Google Scholar